Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $346.85
Previous CloseN/A
Volume614.18K
Average Volume (3M)3.17M
Market Cap
$157.29B
Enterprise Value$190.17B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)38.7
Beta0.50
Next Earnings
Apr 23, 2025EPS Estimate
4.28Last Dividend Ex-Date
Feb 14, 2025Dividend Yield3.07%
Share Statistics
EPS (TTM)7.55
Shares Outstanding537,204,960
10 Day Avg. Volume3,147,115
30 Day Avg. Volume3,171,986
Standard Deviation0.07
R-Squared0.17
Alpha0.00294
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.71
Price to Cash Flow (P/CF)8.20
P/FCF Ratio7.30
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda14.28
Forecast
1Y Price Target
$328.75Price Target Upside10.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
BiosimilarsBiosimilars grew 16% year over year to $2.2 billion and are expected to continue growing in 2025, especially with new launches.
Financial PerformanceNon-GAAP EPS of $5.31 exceeded expectations, indicating strong financial performance.
Product PerformanceStrong key growth driver momentum highlighted by the performance of Repatha and EVENITY.
Bears Say
Clinical HoldThe Phase 1 study of AMG 513 for obesity has been placed on clinical hold by the FDA.
Operating MarginsOperating margin erosion is expected for the next several years, reflecting ramped up obesity R&D spending, along with some generic decay.
ValuationThe company trades at a P/E multiple that is slightly above average, with a LT growth profile that is at or below average.
---
Ownership Overview
0.18% Insiders
21.42% Mutual Funds
18.60% Other Institutional Investors
32.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $157.29B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Apr 23, 2025 which is in 61 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 04, 2025. The company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.091 by $0.219.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.07%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 4.28.
How many shares outstanding does Amgen have?
Amgen has 537,204,960 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.31 in its last earnings report, beating expectations of $5.091. Following the earnings report the stock price went up 6.502%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$328.75 (10.34% Upside)
$328.75 (10.34% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 84%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 287.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.88%
12-Months-Change
Fundamentals
Return on Equity
69.59%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in 2024 with significant growth in product sales, particularly in oncology and biosimilars. The successful integration of Horizon and robust financial results further reinforce Amgen's position for continued growth. However, challenges such as the upcoming patent expiration for denosumab and expected price declines pose potential risks.Read More>---
AMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$328.75
▲(10.34% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
25/35 ratings generated profit
1 Year Average Return
+12.08%
reiterated a buy rating 18 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +12.08% per trade.
---